TrovaGene Company Profile (NASDAQ:TROV)

About TrovaGene (NASDAQ:TROV)

TrovaGene logoTrovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TROV
  • CUSIP: N/A
  • Web: www.trovagene.com
Capitalization:
  • Market Cap: $20.17 million
  • Outstanding Shares: 30,972,000
Average Prices:
  • 50 Day Moving Avg: $0.84
  • 200 Day Moving Avg: $1.81
  • 52 Week Range: $0.65 - $5.98
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.79
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $355,623.00
  • Price / Sales: 56.71
  • Book Value: $0.35 per share
  • Price / Book: 1.89
Profitability:
  • EBIDTA: ($35,520,000.00)
  • Net Margins: -9,703.32%
  • Return on Equity: -104.43%
  • Return on Assets: -63.04%
Debt:
  • Debt-to-Equity Ratio: 0.58%
  • Current Ratio: 7.31%
  • Quick Ratio: 7.31%
Misc:
  • Average Volume: 390,662 shs.
  • Beta: 0.8
  • Short Ratio: 12.22
 

Frequently Asked Questions for TrovaGene (NASDAQ:TROV)

What is TrovaGene's stock symbol?

TrovaGene trades on the NASDAQ under the ticker symbol "TROV."

How were TrovaGene's earnings last quarter?

TrovaGene Inc (NASDAQ:TROV) issued its earnings results on Tuesday, May, 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.29) by $0.07. The company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.34 million. TrovaGene had a negative return on equity of 104.43% and a negative net margin of 9,703.32%. View TrovaGene's Earnings History.

Where is TrovaGene's stock going? Where will TrovaGene's stock price be in 2017?

3 analysts have issued 1 year target prices for TrovaGene's stock. Their predictions range from $1.80 to $8.00. On average, they expect TrovaGene's stock price to reach $4.45 in the next twelve months. View Analyst Ratings for TrovaGene.

What are analysts saying about TrovaGene stock?

Here are some recent quotes from research analysts about TrovaGene stock:

  • 1. Maxim Group analysts commented, "The in-licensing of PCM-075 (Polo-like Kinase 1 Inhibitor, PLK1) from Nerviano Medical Sciences marked a new chapter for Trovagene as a company in precision cancer therapeutics, targeting acute myeloid leukemia (AML). We spent an evening with Trovagene Management to discuss the program in AML, the clinical path forward and how the company will leverage its knowledge- base in precision cancer monitoring (PCM) to develop PCM-075. There are multiple factors that we see as de-risking and in our view position Tovagene for success in AML. 1. The clinical path forward for a PLK inhibitor in AML has been paved by Boehringer Ingelheim’s (BI) Volasertib. A P1/2 (N=50) dose-ranging and efficacy study is expected to initiate in 2017 (data in 2018). Pending positive data, a P2/3 registration study (N=600) would likely follow. 2. Safety: Volasertib as a pan-PLK inhibitor with IV-only administration and a long half-life induced patient deaths (infections). PCM-075 only targets PLK1 (critical for cancer cell survival), has a 5X shorter half life and is oral. As such PCM-075 may be a safer, more efficacious option. 3. Precision Cancer Monitoring, PCM: Trovagene has the advantage of leveraging its existing AML cancer mutation (NPMI) test that can determine the therapeutic response to PCM-075. The company will also use the PCM platform to develop an AML multi-gene panel. Conclusion. Trovagene is now a therapeutics company and has a distinct advantage in being able to leverage its precision cancer monitoring platform to track therapeutic responses to its drug, PCM-075." (5/5/2017)
  • 2. According to Zacks Investment Research, "Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. " (3/15/2017)
  • 3. Cantor Fitzgerald analysts commented, "The partnership with Boreal Genomics is an important milestone for the company, in our view. Per the long-term supply and distribution agreement, 1) TROV commits upfront and milestone payments totaling $1M, 2) TROV has global distribution rights in blood and exclusively in urine for least ten years, and 3) TROV and Boreal will form a joint effort to bring the assay kits and systems through the necessary regulatory pathways for approval. Importantly, TROV continues to target the analytical validation of its initial panel by the end of 2016 and plans to launch a series of cancer-specific multigene ctDNA urine and blood panels, in partnership with Boreal, in 2017. For more details on TROV’s commercialization strategy, please see our September 30, 2016 note. The OnTarget platform separates target mutations from the wild-type. In a one-hour process, the sample is injected into a gel matrix containing short oligo probes that are complementary to the target mutations. The temperature is increased to the melting temperature of the target-probe duplex and target mutations are separated by repeated hybridization in an alternating electric field. Target alleles are collected in the extraction chamber, while the wild-type is removed with more than 1M fold enrichment (and as high as 10M fold)." (11/30/2016)

Who are some of TrovaGene's key competitors?

Who owns TrovaGene stock?

TrovaGene's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.50%), KCG Holdings Inc. (0.68%), Geode Capital Management LLC (0.64%), Prospera Financial Services Inc (0.45%), Two Sigma Securities LLC (0.39%) and Bank of New York Mellon Corp (0.30%). Company insiders that own TrovaGene stock include Antonius Schuh, Bridger Management, Llc, Mark Erlander, Stanley Tennant, Steve Zaniboni and William J Welch. View Institutional Ownership Trends for TrovaGene.

Who sold TrovaGene stock? Who is selling TrovaGene stock?

TrovaGene's stock was sold by a variety of institutional investors in the last quarter, including Prospera Financial Services Inc and Bank of New York Mellon Corp. View Insider Buying and Selling for TrovaGene.

Who bought TrovaGene stock? Who is buying TrovaGene stock?

TrovaGene's stock was bought by a variety of institutional investors in the last quarter, including KCG Holdings Inc., Two Sigma Securities LLC, Geode Capital Management LLC and Vanguard Group Inc.. Company insiders that have bought TrovaGene stock in the last two years include Antonius Schuh, Bridger Management, Llc, Mark Erlander, Stanley Tennant, Steve Zaniboni and William J Welch. View Insider Buying and Selling for TrovaGene.

How do I buy TrovaGene stock?

Shares of TrovaGene can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of TrovaGene stock cost?

One share of TrovaGene stock can currently be purchased for approximately $0.65.

Analyst Ratings

Consensus Ratings for TrovaGene (NASDAQ:TROV) (?)
Ratings Breakdown: 1 Sell Rating, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $4.45 (583.46% upside)

Analysts' Ratings History for TrovaGene (NASDAQ:TROV)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/25/2017Maxim GroupSet Price TargetBuy$4.00HighView Rating Details
3/18/2017Cantor FitzgeraldSet Price TargetBuy$8.00HighView Rating Details
3/16/2017Piper Jaffray CompaniesDowngradeNeutral -> UnderweightHighView Rating Details
3/10/2017S&P Equity ResearchBoost Price Target$1.55 -> $1.80N/AView Rating Details
5/12/2016Leerink SwannReiterated RatingHoldN/AView Rating Details
4/28/2016ArgusDowngradeBuy -> HoldN/AView Rating Details
3/29/2016Avondale PartnersReiterated RatingMarket Perform$6.00N/AView Rating Details
3/11/2016Janney Montgomery ScottDowngradeBuy -> NeutralN/AView Rating Details
2/22/2016Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for TrovaGene (NASDAQ:TROV)
Earnings by Quarter for TrovaGene (NASDAQ:TROV)
Earnings History by Quarter for TrovaGene (NASDAQ:TROV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2016Q116($0.29)($0.36)$0.34 million$0.12 millionViewListenView Earnings Details
3/10/2016Q415($0.25)($0.26)$0.14 million$0.08 millionViewListenView Earnings Details
8/10/2015Q215($0.24)($0.41)$0.05 millionViewListenView Earnings Details
5/5/2015($0.23)($0.24)$0.08 million$0.13 millionViewN/AView Earnings Details
3/12/2015Q414($0.26)($0.25)$0.06 millionViewN/AView Earnings Details
11/6/2014Q3 14($0.25)($0.28)$0.05 million$0.06 millionViewN/AView Earnings Details
8/7/2014($0.24)($0.18)$0.05 million$0.06 millionViewN/AView Earnings Details
5/12/2014($0.23)($0.17)$0.05 million$0.11 millionViewN/AView Earnings Details
3/17/2014Q413($0.19)($0.05)$0.15 million$0.05 millionViewN/AView Earnings Details
11/14/2013Q313($0.22)($0.25)ViewN/AView Earnings Details
8/14/2013Q213($0.15)($0.34)ViewN/AView Earnings Details
5/14/2013Q113($0.09)($0.07)$0.03 million$0.12 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for TrovaGene (NASDAQ:TROV)
Current Year EPS Consensus Estimate: $-1.0400 EPS
Next Year EPS Consensus Estimate: $-0.8200 EPS

Dividends

Dividend History for TrovaGene (NASDAQ:TROV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for TrovaGene (NASDAQ:TROV)
Insider Ownership Percentage: 10.70%
Institutional Ownership Percentage: 27.88%
Insider Trades by Quarter for TrovaGene (NASDAQ:TROV)
Institutional Ownership by Quarter for TrovaGene (NASDAQ:TROV)
Insider Trades by Quarter for TrovaGene (NASDAQ:TROV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/19/2016Stanley TennantDirectorBuy10,000$2.10$21,000.00View SEC Filing  
12/16/2016Stanley TennantDirectorBuy14,966$2.00$29,932.00View SEC Filing  
12/16/2016William J WelchCEOBuy4,750$2.09$9,927.50View SEC Filing  
12/14/2016Mark ErlanderInsiderBuy5,000$2.08$10,400.00View SEC Filing  
8/12/2015Antonius SchuhCEOBuy20,000$5.45$109,000.00View SEC Filing  
8/12/2015Stanley TennantDirectorBuy10,000$6.06$60,600.00View SEC Filing  
8/12/2015Steve ZaniboniCFOBuy15,000$5.43$81,450.00View SEC Filing  
7/17/2015Bridger Management, LlcMajor ShareholderBuy140,000$8.75$1,225,000.00View SEC Filing  
4/2/2015Bridger Management, LlcMajor ShareholderBuy300,000$6.90$2,070,000.00View SEC Filing  
2/27/2015Bridger Management, LlcMajor ShareholderBuy263,286$5.36$1,411,212.96View SEC Filing  
2/6/2015Bridger Management, LlcMajor ShareholderBuy444,444$4.50$1,999,998.00View SEC Filing  
6/9/2014Steve ZaniboniCFOBuy6,329$3.95$24,999.55View SEC Filing  
9/3/2013Thomas Phd AdamsDirectorSell19,200$8.19$157,248.00View SEC Filing  
11/30/2012Stanley TennantDirectorBuy25,000$4.82$120,500.00View SEC Filing  
8/20/2012Gabriel CerroneDirectorBuy7,800$2.35$18,330.00View SEC Filing  
8/16/2012Gabriel CerroneDirectorBuy15,000$2.24$33,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for TrovaGene (NASDAQ:TROV)
Latest Headlines for TrovaGene (NASDAQ:TROV)
Source:
DateHeadline
streetinsider.com logoTrovagene (TROV) Says Phase 1 Safety Study Supports Planned Development of PCM-075 in AML
www.streetinsider.com - May 27 at 6:23 AM
streetinsider.com logoTrovagene (TROV) Says Phase 1 Safety Study Supports Planned ... - StreetInsider.com
www.streetinsider.com - May 26 at 7:53 AM
finance.yahoo.com logoPhase 1 Safety Study Supports Planned Development of PCM-075 in AML
finance.yahoo.com - May 26 at 7:53 AM
finance.yahoo.com logoETFs with exposure to TrovaGene, Inc. : May 25, 2017
finance.yahoo.com - May 26 at 7:53 AM
americanbankingnews.com logoTrovaGene Inc (TROV) Given a $4.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - May 25 at 8:36 PM
finance.yahoo.com logoTrovaGene, Inc. :TROV-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
finance.yahoo.com - May 25 at 5:29 AM
prnewswire.com logoTrovagene to Present at the 7th Annual LD Micro Invitational Conference on June 7, 2017 in Los Angeles - PR Newswire (press release)
www.prnewswire.com - May 23 at 8:44 AM
finance.yahoo.com logoTrovagene to Present at the 7th Annual LD Micro Invitational Conference on June 7, 2017 in Los Angeles
finance.yahoo.com - May 23 at 8:44 AM
americanbankingnews.com logoTrovaGene Inc (TROV) PT Set at $4.00 by Maxim Group
www.americanbankingnews.com - May 13 at 5:50 PM
finance.yahoo.com logoEdited Transcript of TROV earnings conference call or presentation 10-May-17 9:00pm GMT
finance.yahoo.com - May 12 at 2:40 AM
finance.yahoo.com logoTrovagene Announces First Quarter 2017 Company Highlights and Financial Results
finance.yahoo.com - May 11 at 2:29 AM
finance.yahoo.com logoTrovagene reports 1Q loss
finance.yahoo.com - May 11 at 2:29 AM
americanbankingnews.com logoTrovaGene Inc (TROV) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - May 8 at 9:40 AM
americanbankingnews.com logoTrovaGene Inc (TROV) Earns Buy Rating from Maxim Group
www.americanbankingnews.com - May 5 at 6:14 PM
americanbankingnews.com logoTrovaGene (TROV) Getting Positive Press Coverage, Report Shows
www.americanbankingnews.com - May 2 at 11:44 AM
americanbankingnews.com logoTrovaGene (TROV) Given Daily News Sentiment Score of 0.32
www.americanbankingnews.com - April 27 at 1:06 PM
prnewswire.com logoTrovagene to Announce First Quarter 2017 Financial Results and Host Conference Call on Wednesday, May 10, 2017 - PR Newswire (press release)
www.prnewswire.com - April 27 at 9:22 AM
streetinsider.com logoForm 8-K Trovagene, Inc. For: Apr 26 - StreetInsider.com
www.streetinsider.com - April 27 at 9:22 AM
finance.yahoo.com logoTrovagene to Announce First Quarter 2017 Financial Results and Host Conference Call on Wednesday, May 10, 2017 - Yahoo Finance
finance.yahoo.com - April 26 at 8:40 AM
prnewswire.com logoTrovagene to Present at the Pioneers 2017 Joseph Gunnar Conference on May 2, 2017 in New York City - PR Newswire (press release)
www.prnewswire.com - April 26 at 8:40 AM
finance.yahoo.com logoTrovagene to Announce First Quarter 2017 Financial Results and Host Conference Call on Wednesday, May 10, 2017
finance.yahoo.com - April 26 at 8:40 AM
finance.yahoo.com logoTrovagene to Present at the Pioneers 2017 Joseph Gunnar Conference on May 2, 2017 in New York City
finance.yahoo.com - April 25 at 9:12 AM
americanbankingnews.com logoTrovaGene Inc (TROV) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 24 at 9:40 PM
americanbankingnews.com logoTrovaGene (TROV) Getting Favorable Press Coverage, Report Finds
www.americanbankingnews.com - April 23 at 4:21 PM
finance.yahoo.com logoETFs with exposure to TrovaGene, Inc. : April 20, 2017
finance.yahoo.com - April 20 at 10:40 PM
americanbankingnews.com logoTrovaGene (TROV) Given Daily Media Sentiment Rating of 0.14
www.americanbankingnews.com - April 16 at 10:41 AM
prnewswire.com logoTrovagene Announces the Addition of Dr. Sandra Silberman to its Clinical Advisory Board - PR Newswire (press release)
www.prnewswire.com - April 15 at 11:28 AM
finance.yahoo.com logoTrovagene Announces the Addition of Dr. Sandra Silberman to its Clinical Advisory Board
finance.yahoo.com - April 13 at 8:12 PM
americanbankingnews.com logoTrovaGene (TROV) Earns Daily Media Impact Rating of 0.34
www.americanbankingnews.com - April 13 at 4:40 PM
americanbankingnews.com logoTrovaGene Inc (TROV) Rating Increased to Buy at Maxim Group
www.americanbankingnews.com - April 12 at 2:01 PM
finance.yahoo.com logoETFs with exposure to TrovaGene, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 6:05 PM
americanbankingnews.com logoTrovaGene Inc (TROV) Short Interest Update
www.americanbankingnews.com - April 6 at 1:28 PM
americanbankingnews.com logoTrovaGene Inc (TROV) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 29 at 12:35 PM
biz.yahoo.com logoTROVAGENE, INC. Files SEC form 8-K, Regulation FD Disclosure
biz.yahoo.com - March 28 at 8:47 AM
finance.yahoo.com logoTrovagene to Present at The MicroCap Conference on April 4, 2017 in New York City
finance.yahoo.com - March 27 at 8:37 AM
americanbankingnews.com logoPiper Jaffray Companies Lowers TrovaGene Inc (TROV) to Underweight
www.americanbankingnews.com - March 22 at 8:20 AM
finance.yahoo.com logoTROVAGENE, INC. Financials
finance.yahoo.com - March 21 at 8:05 PM
us.rd.yahoo.com logoTrovagene to Present at the Sidoti & Company Spring 2017 Convention
us.rd.yahoo.com - March 21 at 9:51 AM
capitalcube.com logoTrovaGene, Inc. :TROV-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
us.rd.yahoo.com - March 21 at 9:51 AM
us.rd.yahoo.com logoEdited Transcript of TROV earnings conference call or presentation 15-Mar-17 9:00pm GMT
us.rd.yahoo.com - March 17 at 3:35 AM
us.rd.yahoo.com logoTrovaGene downgraded by Piper Jaffray and Maxim Group
us.rd.yahoo.com - March 17 at 3:35 AM
americanbankingnews.com logoTrovaGene Inc (TROV) Lowered to Underweight at Piper Jaffray Companies
www.americanbankingnews.com - March 17 at 1:22 AM
americanbankingnews.com logoMaxim Group Lowers TrovaGene Inc (TROV) to Hold
www.americanbankingnews.com - March 16 at 12:19 PM
seekingalpha.com logoTrovagene nabs rights to leukemia candidate from Nerviano Medical - Seeking Alpha
seekingalpha.com - March 16 at 3:29 AM
nasdaq.com logoEarnings Reaction History: TrovaGene, Inc., 75.0% Follow-Through ... - Nasdaq
www.nasdaq.com - March 16 at 3:29 AM
reuters.com logoBRIEF-Trovagene, Nerviano announce license agreement for therapeutic candidate PCM-075
www.reuters.com - March 15 at 10:28 PM
us.rd.yahoo.com logoTrovagene and Nerviano Announce License Agreement for therapeutic candidate PCM-075
us.rd.yahoo.com - March 15 at 10:28 PM
us.rd.yahoo.com logoTrovagene Reports Fourth Quarter and Year End 2016 Financial Results
us.rd.yahoo.com - March 15 at 10:28 PM
biz.yahoo.com logoTROVAGENE, INC. Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 15 at 10:28 PM
biz.yahoo.com logoTROVAGENE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statements
us.rd.yahoo.com - March 15 at 10:28 PM

Social

Chart

TrovaGene (TROV) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff